usaconsumernetworkx130

ARTHRITIS MEDICATION XELJANZ® & XELJANZ XR® LINKED TO SERIOUS SIDE EFFECTS.

ARTHRITIS MEDICATION XELJANZ® & XELJANZ XR® LINKED TO SERIOUS SIDE EFFECTS.

• PULMONARY EMBOLISM (PE)
• DEEP VEIN THROMBOSIS (DVT)
• STROKE
• BLOOD CLOTS
• AND MUCH MORE

Have You Or A Loved One Been Diagnosed With A Pulmonary Embolism, Deep Vein Thrombosis, Or More After Taking Xeljanz®? If So, You May Be Entitled To Compensation.

FREE CLAIM ELIGIBILITY REVIEW

By clicking the "GET MY FREE CASE REVIEW" button, I consent to receive recurring autodialed and/or pre-recorded telemarketing calls and/or text messages from USAConsumerNetwork or our partners in order to discuss my legal options and at the telephone number I provided. I also consent to the USAConsumerNetwork Privacy Policy and Terms of Use. I understand that I may receive a call even if my telephone number is listed on a Do Not Call list and that my consent is not a requirement of purchase. I understand that my telephone company may impose charges on me for these contacts and that I can revoke this consent at any time. For SMS campaigns: Text STOP to cancel and HELP for help. Msg & data rates may apply. Recurring msgs up to 9 msgs per month.

YOU OR A LOVED ONE MAY BE ELIGIBLE FOR A SETTLEMENT

Pfizer, the makers of Xeljanz®, never performed human studies on their drug. Additionally, multiple studies have found that taking Xeljanz® at certain doses can dramatically increase a person's chances of a blood clot.

PFIZER®

Failed to warn doctors and patients about the risks behind Xeljanz® and deadly side effects such as blood clots and pulmonary embolisms

The Risks Behind Xeljanz®

The active ingrediants in Xeljanz® are designed to oppress a patient's immune system, which can lead to multiple side effects. Recently, the FDA reeleased a safety alert stating that consuming Xeljanz® at certain levels can increase the change of blood clots. Patients were never informed of these deadly risks.

A blood clot with a white xeljanz pill in front

FDA issues warning about xeljanz® and blood clots
(2017) 

European Union Rejects Xeljanz® for RA Treatment
(2013)

Xeljanz® is approved for use in the United States
(2012)

First-ever clinical trails of Xeljanz®
(2002)

100% FREE CASE EVALUATION. SEE IF YOU QUALIFY TODAY!

Please seek the advice of a medical professional before making health care decisions. This advertisement is not associated with Pfizer®, Xeljanz®, Xeljanz XR®, or any government agency.

usaconsumernetworkx260

Helping Consumers Win.

ATTORNEY ADVERTISING. This Website is not intended to provide medical advice. Consult your doctor or physician before starting or stopping any medication.

Discontinuing a prescribed medication without your doctor’s advice can result in injury or death. Recoveries are not an indication of future results. Every case is evaluated on its own facts and circumstances. Valuation depends on facts, injuries, jurisdiction, venue, witnesses, parties, and testimony, among other factors. No representation is made that the quality of legal services to be performed is greater than the quality of legal services performed by other lawyers. USA Consumer Network does not itself provide legal services. Cases will be referred to third party attorneys and law firms. Do not rely on this advertisement in making any medical decision. Please call your physician before making any medical decision, including altering your use of any drug. Court costs and case expenses may be the responsibility of the client. Not available in all states. This advertisement is not intended as a testimonial, endorsement or dramatization, and does not constitute a guarantee, warranty, or prediction regarding the outcome of your legal matter, either express or implied. Anyone considering a lawyer should independently investigate the lawyers' credentials and ability, and not rely upon advertisements or self-proclaimed expertise.

© 2020 USA Consumer Network. All Rights Reserved.

Contact

1968 S Coast Highway
#1383
Laguna Beach, CA 92651
United States

hello@usaconsumernetwork.com

Scroll to Top